
Social Security Could Run Out by 2034—Here Are 8 Places To Grow Your Money
Imagine losing nearly a quarter of your monthly income just as you're about to retire.
That's the reality millions of Americans could face if Congress doesn't shore up Social Security before the trust fund runs dry in 2034. According to the latest government estimates, retirees could see automatic cuts of around 23% to their benefits.
While lawmakers argue over potential fixes, one question becomes urgent: How do you plan for retirement when the system you're counting on is in trouble?
There are ways to protect yourself, whether you're just beginning to save or closing in on retirement.
Social Security has never been a perfect system, but it's long served as the foundation of retirement income for most Americans.
Today, over 66 million people receive monthly benefits. The problem is that the system is paying out more than it's taking in. This trend has been fueled by longer life expectancies, lower birth rates and a wave of Baby Boomer retirements.
According to the 2024 Trustees Report, the Old-Age and Survivors Insurance (OASI) Trust Fund will be depleted by 2034. If nothing changes, the program will rely solely on incoming payroll taxes to fund benefits, which will only cover about 77% of scheduled payments.
In other words, retirees could see a nearly one-quarter cut to their monthly income.
A cut to Social Security would hit many households hard, especially older Americans, since nearly 4 in 10 men and almost half of women over 65 rely on it for at least half of their income.
Building a retirement plan that doesn't depend entirely on Social Security is more essential than ever. Here are key savings and investment tools that can help you stay secure, even if benefits are reduced.
If you're holding cash in a traditional savings account, you're likely earning less than 1% interest. High-yield savings accounts , on the other hand, can offer 4% APY or more, depending on the provider.
HYSAs are insured by the Federal Deposit Insurance Corp. (FDIC), meaning your deposits (up to $250,000 per bank) are protected even if the institution fails. They're ideal for emergency savings, short-term goals, or building a liquid cushion while earning competitive interest.
Look for: No monthly fees, low minimums and rates around 4%.
Roth IRAs are one of the most flexible and tax-efficient ways to save for retirement. Contributions are made with after-tax dollars, and withdrawals in retirement are tax-free.
Traditional IRAs work the opposite way: Contributions are often tax-deductible, but withdrawals in retirement are taxed as income.
Having both gives you tax diversification in retirement, especially if Social Security payments are reduced.
2025 contribution limits: Up to $7,000 per year ($8,000 if you're 50 or older), subject to income limits.
CDs are low-risk savings products that let you lock in a fixed interest rate for a set period of time. In 2025, CD rates are still attractive, with many offering 5% or higher for 1-year terms.
If you're worried about market volatility or just want to safeguard a portion of your savings, a CD ladder can help. This strategy involves opening multiple CDs with staggered maturity dates, giving you access to your money at regular intervals while maximizing interest.
Tip: Choose a no-penalty CD if you think you might need early access.
Despite recent market swings, workplace retirement plans remain a critical part of long-term retirement savings, especially if your employer offers a match. That match is essentially free money and should be maxed out if possible.
401(k)s are common in the private sector, while 403(b)s serve employees in public schools and certain nonprofits. Both offer tax-deferred growth, and many employers now offer Roth versions for tax-free withdrawals in retirement.
2025 contribution limits: Up to $23,500 annually ($30,500 if age 50+), plus employer match.
Money-market mutual funds are a low-risk place to park cash while earning a bit more interest than a standard savings account. These funds invest in short-term, high-quality debt and are commonly available through brokerage accounts.
They're a good option for short-term savings goals or as a cash-equivalent portion of a diversified portfolio.
Tip: Unlike HYSAs, money-market funds are not FDIC-insured, but they're still considered very low risk.
If you're not sure how to allocate your investments, robo-advisors can build and manage a diversified portfolio for you automatically. They typically use low-cost ETFs and adjust based on your goals, timeline, and risk tolerance.
This is a great option for hands-off investors who want to stay on track for retirement without paying high advisory fees.
Watch for: Expense ratios under 0.25% and platforms with low or no minimums.
If you have a high-deductible health plan, an HSA is one of the most powerful and underused savings tools. Not only does it offer a triple tax benefit, but many HSA providers also allow you to invest your balance once it exceeds a threshold (typically $1,000 or $2,000).
Invested HSA funds can grow tax-free for decades and be used for healthcare costs in retirement, or withdrawn after age 65 like a traditional IRA.
2025 contribution limits: $4,300 for individuals, $8,550 for families (plus $1,000 catch-up if over 55).
If you're looking to invest on your own, the right online broker can make a big difference. The best online brokers for beginners offer intuitive platforms, strong customer support, commission-free trades and robust educational tools.
Start by looking for a platform with no account minimum, low fees, and a wide range of investment options, including index funds, ETFs, and retirement accounts.
Popular picks: Fidelity, Charles Schwab, SoFi and Robinhood.
Everyone's retirement path is different, but here's how you can think about saving if you're worried about Social Security shortfalls. Open a Roth IRA and automate monthly contributions
Start an emergency fund in a HYSA
Contribute to your 401(k), especially if you get a match
Consider a robo-advisor for easy, diversified investing Max out 401(k) and IRA contributions if possible
Diversify with CDs, money-market funds and HSAs
Use catch-up contributions and estimate your Social Security benefits
Explore low-fee online brokers or robo-advisors Delay Social Security if you can to boost your monthly payout
Shift some assets to safer options like HYSAs and short-term CDs
Review your HSA balance and plan for healthcare costs
Consider consolidating accounts at a beginner-friendly broker
The possibility of Social Security cuts is real, but it doesn't have to derail your retirement.
By taking steps now, like boosting your 401(k), opening a Roth IRA, and moving idle cash into a high-yield savings account, you can prepare for the future, even if the system falls short.
The earlier you act, the more options you'll have. Social Security may be uncertain, but your personal savings strategy doesn't have to be.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Trump Jr.-backed GrabAGun recovers slightly after sharp NYSE debut drop
(Reuters) -Donald Trump Jr.-backed GrabAGun's shares inched up 2% in premarket trading on Thursday, recovering slightly after tumbling 24% in their New York Stock Exchange debut following a blank-check merger. According to the gun retailer's prospectus filed with the U.S. securities regulator, Trump Jr., the oldest son of President Donald Trump, owns about 300,000 shares in the company, currently worth roughly $4 million. Trump Jr. also sits on the board of the online retailer of firearms, ammunition and gun accessories. The Trump family's business interests span real estate, hospitality, media, and increasingly, politically aligned ventures tied to gun rights and conservative consumerism. From Donald Trump's sprawling portfolio of golf courses and hotels to Trump Media & Technology Group's volatile public debut - and now Trump Jr.'s stake in GrabAGun - the family's brand has been used to tap into a loyal base of supporters and investors. These ventures, often closely tied to the president's political identity, have drawn scrutiny from regulators and investors. "What we're doing with GrabAGun would have been unthinkable four years ago at the height of wokeness in corporate America," Trump Jr. said in a post on X. Founded in 2010, the company offers an assortment of sporting firearms, ammunition and accessories. It has said it expects to benefit from a shift to online shopping by younger firearm enthusiasts. SPACs allow their shareholders to redeem their shares and get their money back if they do not like the proposed merger target. Colombier said it had seen "near-zero" such redemptions, signaling "clear confidence" in the GrabAGun business. The merger positions GrabAGun among a growing group of right-leaning companies such as Trump Media, Rumble and Chain Bridge Bancorp that have gone public in recent years.

Yahoo
10 minutes ago
- Yahoo
Abbott Reports Second-Quarter 2025 Results
Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26 Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increase Reported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increase ABBOTT PARK, Ill., July 17, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2025. Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1. Second-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.26, which excludes specified items and reflects double-digit growth compared to the prior year. First-half sales increased 5.7 percent on a reported basis, 6.9 percent on an organic basis, or 7.9 percent when excluding COVID-19 testing-related sales2. Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales. Abbott projects full-year 2025 adjusted diluted EPS of $5.10 to $5.20, which reflects double-digit growth at the midpoint. In April, Abbott completed enrollment ahead of schedule in its FlexPulse U.S. IDE trial, which is designed to evaluate the TactiFlex™ Duo Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib). In April, Abbott announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) clinical feasibility study. This study was the world's first assessment of a leadless pacemaker delivering conduction pacing, which produces pacing that closely mimics the heart's natural electrical rhythm and represents a new treatment option for people with irregular heart rhythms. In May, Abbott announced U.S. Food and Drug Administration (FDA) approval of the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system, a first-of-its-kind device to help treat people with mitral valve disease. Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028. "Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline," said Robert B. Ford, chairman and chief executive officer, Abbott. "We see this momentum carrying into 2026." SECOND-QUARTER BUSINESS OVERVIEWManagement believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase. Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. Second Quarter 2025 Results (2Q25)Sales 2Q25 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices U.S. 4,276957811—2,503 International 6,8661,2551,3621,3832,866 Total reported 11,1422,2122,1731,3835,369 % Change vs. 2Q24U.S. 8.72.6(0.1)n/a14.6 International 6.63.1(1.5)6.912.4 Total reported 7.42.9(1.0)6.913.4 Impact of foreign exchange 0.5(0.5)0.4(0.8)1.2 Organic 6.93.4(1.4)7.712.2 Impact of COVID-19 testing sales 1 (0.6)—(2.2)—— Organic (excluding COVID-19 tests) 7.53.40.87.712.2 Organic U.S. 8.72.6(0.1)n/a14.6 International 5.84.0(2.2)7.710.1 First Half 2025 Results (1H25)Sales 1H25 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices U.S. 8,4441,9121,682—4,842 International 13,0562,4462,5452,6435,422 Total reported 21,5004,3584,2272,64310,264 % Change vs. 1H24U.S. 8.55.6(3.5)n/a14.8 International 3.91.6(4.5)4.99.1 Total reported 5.73.3(4.1)4.911.7 Impact of foreign exchange (1.1)(1.5)(0.9)(2.9)(0.7) Impact of business exit* (0.1)(0.3)——— Organic 6.95.1(3.2)7.812.4 Impact of COVID-19 testing sales 2 (1.0)—(3.9)—— Organic (excluding COVID-19 tests) 7.95.10.77.812.4 Organic U.S. 8.76.4(3.5)n/a14.8 International 5.84.1(3.0)7.810.3 Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue. *Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024. NutritionSecond Quarter 2025 Results (2Q25)Sales 2Q25 ($ in millions) TotalPediatricAdult U.S. 957587370 International 1,255467788 Total reported 2,2121,0541,158 % Change vs. 2Q24U.S. 2.64.20.2 International 3.1(5.7)9.2 Total reported 2.9(0.4)6.1 Impact of foreign exchange (0.5)(0.6)(0.5) Organic 3.40.26.6 U.S. 2.64.20.2 International 4.0(4.5)9.8 Worldwide Nutrition sales increased 2.9 percent on a reported basis and 3.4 percent on an organic basis in the second quarter. Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1 percent on a reported basis and 6.6 percent on an organic basis, led by strong growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading brand of products designed to meet the nutritional requirements for people with diabetes. First Half 2025 Results (1H25)Sales 1H25 ($ in millions) TotalPediatricAdult U.S. 1,9121,175737 International 2,4469201,526 Total reported 4,3582,0952,263 % Change vs. 1H24U.S. 5.69.00.6 International 1.6(7.0)7.7 Total reported 3.31.35.3 Impact of foreign exchange (1.5)(1.2)(1.6) Impact of business exit* (0.3)—(0.7) Organic 5.12.57.6 U.S. 6.49.02.4 International 4.1(4.6)10.2*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024. DiagnosticsSecond Quarter 2025 Results (2Q25)Sales 2Q25 ($ in millions) TotalCore LaboratoryMolecularPoint of CareRapidDiagnostics U.S. 81135135104321 International 1,3621,0078844223 Total reported 2,1731,358123148544 % Change vs. 2Q24U.S. (0.1)7.35.5(2.0)(7.1) International (1.5)0.5(5.6)(11.9)(6.1) Total reported (1.0)2.2(2.7)(5.1)(6.7) Impact of foreign exchange 0.40.60.70.10.1 Organic (1.4)1.6(3.4)(5.2)(6.8) U.S. (0.1)7.35.5(2.0)(7.1) International (2.2)(0.3)(6.5)(12.1)(6.3) Global Diagnostics sales decreased 1.0 percent on a reported basis, decreased 1.4 percent on an organic basis, and increased 0.8 percent when excluding COVID-19 testing-related sales1. Diagnostics sales growth was impacted by the year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China. COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million in the second quarter of the prior year. Global Core Laboratory Diagnostics sales increased 2.2 percent on a reported basis and increased 1.6 percent on an organic basis. Growth in the quarter was impacted by volume-based procurement programs in China. First Half 2025 Results (1H25)Sales 1H25 ($ in millions) TotalCore LaboratoryMolecularPoint of CareRapidDiagnostics U.S. 1,68268375204720 International 2,5451,85217086437 Total reported 4,2272,5352452901,157 % Change vs. 1H24U.S. (3.5)7.2—(0.3)(12.8) International (4.5)(2.4)(6.1)(4.5)(12.3) Total reported (4.1)0.1(4.4)(1.6)(12.6) Impact of foreign exchange (0.9)(1.2)(1.0)(0.4)(0.6) Organic (3.2)1.3(3.4)(1.2)(12.0) U.S. (3.5)7.2—(0.3)(12.8) International (3.0)(0.7)(4.9)(3.3)(10.7) Established PharmaceuticalsSecond Quarter 2025 Results (2Q25)Sales 2Q25 ($ in millions) TotalKey EmergingMarketsOther U.S. ——— International 1,3831,059324 Total reported 1,3831,059324 % Change vs. 2Q24U.S. n/an/an/a International 6.97.35.9 Total reported 6.97.35.9 Impact of foreign exchange (0.8)(1.4)1.4 Organic 7.78.74.5 U.S. n/an/an/a International 7.78.74.5 Established Pharmaceuticals sales increased 6.9 percent on a reported basis and 7.7 percent on an organic basis in the second quarter. Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 7.3 percent on a reported basis and 8.7 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East. First Half 2025 Results (1H25)Sales 1H25 ($ in millions) TotalKey Emerging MarketsOther U.S. ——— International 2,6432,024619 Total reported 2,6432,024619 % Change vs. 1H24U.S. n/an/an/a International 4.95.72.4 Total reported 4.95.72.4 Impact of foreign exchange (2.9)(3.3)(1.4) Organic 7.89.03.8 U.S. n/an/an/a International 7.89.03.8 Medical DevicesSecond Quarter 2025 Results (2Q25)Sales 2Q25 ($ in millions) TotalRhythmManagementElectro- physiologyHeart FailureVascularStructuralHeartNeuro-modulationDiabetesCare U.S. 2,503340322282283289193794 International 2,86633337886474347611,187 Total reported 5,3696737003687576362541,981 % Change vs. 2Q24U.S. 14.616.512.215.83.012.20.424.5 International 12.45.710.911.25.413.720.417.5 Total reported 13.410.911.514.74.513.04.620.2 Impact of foreign exchange 1.21.11.20.71.01.30.31.7 Organic 12.29.810.314.03.511.74.318.5 U.S. 14.616.512.215.83.012.20.424.5 International 10.13.68.88.43.811.418.714.7 Worldwide Medical Devices sales increased 13.4 percent on a reported basis and 12.2 percent on an organic basis in the second quarter. Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart and Electrophysiology. Several products contributed to the strong performance, including FreeStyle Libre®, Navitor®, TriClip® and AVEIR®. In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4 percent on a reported basis and 19.6 percent on an organic basis. First Half 2025 Results (1H25)Sales 1H25 ($ in millions) TotalRhythm ManagementElectro- physiologyHeartFailureVascularStructuralHeartNeuro-modulationDiabetesCare U.S. 4,8426446215445515713691,542 International 5,4226147081639166421132,266 Total reported 10,2641,2581,3297071,4671,2134823,808 % Change vs. 1H24U.S. 14.814.411.713.24.216.3(1.1)25.7 International 9.11.27.612.63.59.318.513.8 Total reported 11.77.69.513.13.812.52.918.4 Impact of foreign exchange (0.7)(0.4)(0.6)(0.2)(0.7)(0.7)(0.4)(0.7) Organic 12.48.010.113.34.513.23.319.1 U.S. 14.814.411.713.24.216.3(1.1)25.7 International 10.32.08.813.44.810.520.515.0 ABBOTT'S FINANCIAL GUIDANCEAbbott projects full-year 2025 organic sales growth, excluding COVID-19 testing related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales. Abbott projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales. Abbott projects full-year 2025 adjusted diluted earnings per share of $5.10 to $5.20 and third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP. ABBOTT DECLARES 406th CONSECUTIVE QUARTERLY DIVIDENDOn June 13, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.59 per share. Abbott's cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at and on LinkedIn, Facebook, Instagram, X and YouTube. Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day. — Private Securities Litigation Reform Act of 1995 —A Caution Concerning Forward-Looking Statements Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 1. In the second quarter of 2025, total worldwide sales were $11.142 billion, total Diagnostics sales were $2.173 billion and COVID-19 testing-related sales were $55 million. In the second quarter of 2024, total worldwide sales were $10.377 billion, total Diagnostics sales were $2.195 billion and COVID-19 testing-related sales were $102 million. 2. In the first half of 2025, total worldwide sales were $21.500 billion, total Diagnostics sales were $4.227 billion and COVID-19 testing-related sales were $139 million. In the first half of 2024, total worldwide sales were $20.341 billion, total Diagnostics sales were $4.409 billion and COVID-19 testing-related sales were $306 million. Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Second Quarter Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 2Q252Q24% ChangeNet Sales $11,142$10,3777.4 Cost of products sold, excluding amortization expense 4,8544,6035.5Amortization of intangible assets 420471(10.7)Research and development 7256983.9Selling, general, and administrative 3,0912,9365.3Total Operating Cost and Expenses 9,0908,7084.4 Operating Earnings 2,0521,66923.0 Interest expense, net 5058(14.2)Net foreign exchange (gain) loss (11)(6)55.6Other (income) expense, net (137)10n/mEarnings before taxes 2,1501,60733.8Taxes on earnings 37130521.3 1)Net Earnings $1,779$1,30236.7 Net Earnings excluding Specified Items, as described below $2,213$2,00310.5 2)Diluted Earnings per Common Share $1.01$0.7436.5 Diluted Earnings per Common Share, excluding Specified Items, as described below $1.26$1.1410.5 2)Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,7511,751 NOTES: See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. n/m = Percent change is not meaningful. See footnotes on the following section.1) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years. 2) 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $701 million, or $0.40 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses. Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings First Half Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 1H251H24% ChangeNet Sales $21,500$20,3415.7 Cost of products sold, excluding amortization expense 9,3229,0662.8Amortization of intangible assets 840943(10.8)Research and development 1,4411,3824.3Selling, general, and administrative 6,1525,8954.4Total Operating Cost and Expenses 17,75517,2862.7 Operating Earnings 3,7453,05522.6 Interest expense, net 99119(16.4)Net foreign exchange (gain) loss (18)(6)n/mOther (income) expense, net (264)(101)n/mEarnings before taxes 3,9283,04329.1Taxes on earnings 82451659.5 1)Net Earnings $3,104$2,52722.9 Net Earnings excluding Specified Items, as described below $4,132$3,73210.7 2)Diluted Earnings per Common Share $1.77$1.4422.9 Diluted Earnings per Common Share, excluding Specified Items, as described below $2.35$2.1210.8 2)Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,7491,750 NOTES: See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. n/m = Percent change is not meaningful. See footnotes on the following section. 1) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years. 2) 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.205 billion, or $0.68 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses. Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Second Quarter Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 2Q25As Reported(GAAP)SpecifiedItemsAs Adjusted Intangible Amortization $ 420$ (420)$ — Gross Margin 5,8684786,346 R&D 725(20)705 SG&A 3,091(1)3,090 Other (income) expense, net (137)(1)(138) Earnings before taxes 2,1505002,650 Taxes on Earnings 37166437 Net Earnings 1,7794342,213 Diluted Earnings per Share $ 1.01$ 0.25$ 1.26 Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.2Q24As Reported(GAAP)SpecifiedItemsAs Adjusted Intangible Amortization $ 471$ (471)$ — Gross Margin 5,3035065,809 R&D 698(41)657 SG&A 2,936(57)2,879 Other (income) expense, net 10(145)(135) Earnings before taxes 1,6077492,356 Taxes on Earnings 30548353 Net Earnings 1,3027012,003 Diluted Earnings per Share $ 0.74$ 0.40$ 1.14 Specified items reflect intangible amortization expense of $471 million and other net expenses of $278 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items. Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information First Half Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 1H25As Reported(GAAP)SpecifiedItemsAs Adjusted Intangible Amortization $ 840$ (840)$ — Gross Margin 11,33892612,264 R&D 1,441(47)1,394 SG&A 6,152(11)6,141 Other (income) expense, net (264)(36)(300) Earnings before taxes 3,9281,0204,948 Taxes on Earnings 824(8)816 Net Earnings 3,1041,0284,132 Diluted Earnings per Share $ 1.77$ 0.58$ 2.35 Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.1H24As Reported(GAAP)SpecifiedItemsAs Adjusted Intangible Amortization $ 943$ (943)$ — Gross Margin 10,3321,02411,356 R&D 1,382(62)1,320 SG&A 5,895(91)5,804 Other (income) expense, net (101)(171)(272) Earnings before taxes 3,0431,3484,391 Taxes on Earnings 516143659 Net Earnings 2,5271,2053,732 Diluted Earnings per Share $ 1.44$ 0.68$ 2.12 Specified items reflect intangible amortization expense of $943 million and other net expenses of $405 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items. A reconciliation of the second-quarter tax rates for 2025 and 2024 is shown below:2Q25($ in millions) Pre-Tax IncomeTaxes on EarningsTax RateAs reported (GAAP) $ 2,150$ 37117.3 % 1) Specified items 50066Excluding specified items $ 2,650$ 43716.5 %2Q24($ in millions) Pre-Tax IncomeTaxes on EarningsTax RateAs reported (GAAP) $ 1,607$ 30519.0 % 2) Specified items 74948Excluding specified items $ 2,356$ 35315.0 %1) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 2) 2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years. A reconciliation of the year-to-date tax rates for 2025 and 2024 is shown below:1H25($ in millions) Pre-Tax IncomeTaxes on EarningsTax RateAs reported (GAAP) $ 3,928$ 82421.0 % 3) Specified items 1,020(8)Excluding specified items $ 4,948$ 81616.5 %1H24($ in millions) Pre-Tax IncomeTaxes on EarningsTax RateAs reported (GAAP) $ 3,043$ 51617.0 % 4) Specified items 1,348143Excluding specified items $ 4,391$ 65915.0 %3) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 4) 2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years. Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation First Half Ended June 30, 2025 and 2024 ($ in millions) (unaudited)1H251H24% Change vs. 1H24 Non-GAAP AbbottReportedAbbott Reported Impactfrom businessexit (a) Adjusted RevenueReportedAdjusted Organic Total Company21,50020,341 (13) 20,3285.75.8 6.9 U.S.8,4447,780 (13) 7,7678.58.7 8.7 Intl13,05612,561 — 12,5613.93.9 5.8 Total Nutrition4,3584,218 (13) 4,2053.33.6 5.1 U.S.1,9121,811 (13) 1,7985.66.4 6.4 Intl2,4462,407 — 2,4071.61.6 4.1 Adult Nutrition2,2632,150 (13) 2,1375.36.0 7.6 U.S.737733 (13) 7200.62.4 2.4 Intl1,5261,417 — 1,4177.77.7 10.2 (a) Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024. Abbott Laboratories and Subsidiaries Details of Specified Items Second Quarter Ended June 30, 2025 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a)Restructuring and Cost Reduction Initiatives (b)Intangible AmortizationOther (c)Total Specifieds Gross Margin $ 1$ 55$ 420$ 2$ 478 R&D —(7)—(13)(20) SG&A (3)1—1(1) Other (income) expense, net (1)———(1) Earnings before taxes $ 5$ 61$ 420$ 14500 Taxes on Earnings (d) 66 Net Earnings $ 434 Diluted Earnings per Share $ 0.25 The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products. d) Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Abbott Laboratories and Subsidiaries Details of Specified Items Second Quarter Ended June 30, 2024 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a)Restructuring and Cost Reduction Initiatives (b)Intangible AmortizationOther (c)Total Specifieds Gross Margin $ 1$ 32$ 471$ 2$ 506 R&D (1)1—(41)(41) SG&A (11)(10)—(36)(57) Other (income) expense, net (147)——2(145) Earnings before taxes $ 160$ 41$ 471$ 77749 Taxes on Earnings (d) 48 Net Earnings $ 701 Diluted Earnings per Share $ 0.40 The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." a) Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the MDR and IVDR requirements for previously approved products and an intangible asset impairment charge. d) Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. Abbott Laboratories and Subsidiaries Details of Specified Items First Half Ended June 30, 2025 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a)Restructuring and Cost Reduction Initiatives (b)Intangible AmortizationOther (c)Total Specifieds Gross Margin $ 1$ 81$ 840$ 4$ 926 R&D (1)(23)—(23)(47) SG&A (6)(6)—1(11) Other (income) expense, net (25)——(11)(36) Earnings before taxes $ 33$ 110$ 840$ 371,020 Taxes on Earnings (d) (8) Net Earnings $ 1,028 Diluted Earnings per Share $ 0.58 The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments. d) Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Abbott Laboratories and Subsidiaries Details of Specified Items First Half Ended June 30, 2024 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a)Restructuring and Cost Reduction Initiatives (b)Intangible AmortizationOther (c)Total Specifieds Gross Margin $ 2$ 74$ 943$ 5$ 1,024 R&D (4)(1)—(57)(62) SG&A (25)(19)—(47)(91) Other (income) expense, net (135)——(36)(171) Earnings before taxes $ 166$ 94$ 943$ 1451,348 Taxes on Earnings (d) 143 Net Earnings $ 1,205 Diluted Earnings per Share $ 0.68 The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." a) Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments. d) Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. View original content: SOURCE Abbott Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
Fifth Third Bancorp's quarterly profit rises on higher interest income
(Reuters) -Fifth Third Bancorp reported a rise in second-quarter profit on Thursday, as lower deposit costs boosted the regional bank's interest income, cushioning a larger buffer for loan losses. An interest rate cutting cycle by the U.S. Federal Reserve in the second half of 2024 has prompted efforts by banks to reduce deposit costs across their portfolios. The company's net interest income (NII) — the difference between what banks pay customers on deposits and what it earns as interest on loans — for the quarter rose 7.8% from a year ago to $1.5 billion. The rise in NII reflected an improving asset mix and repricing of certain fixed-rate assets, with interest expense down 20% compared with the year-ago period. After a rocky start to the quarter when U.S. President Donald Trump's tariffs scuttled dealmaking, executive sentiment has rebounded on hopes for trade deals and potential rate cuts by the Fed. But regional lenders such as Fifth Third depend largely on loans to small businesses and consumers, who are particularly vulnerable to an economic slowdown. The Cincinnati, Ohio-based bank's provision for credit losses jumped to $173 million in the quarter from $97 million a year earlier, as it set aside more funds to account for a potential increase in loan defaults. The lender also benefited from higher fees, with total non-interest income rising 8% to $750 million in the quarter, boosted by a seasonal equity fund return. Net income available to common shareholders rose to $591 million, or 88 cents per share, in the three months ended June 30. It had reported $561 million, or 81 cents per share, a year earlier. Shares of Fifth Third have risen 1.8% YTD, as of last close, compared with a 10.7% gain in the KBW Bank index.